A screening trial of amantadine as a medication for cocaine dependence

摘要: This screening trial evaluated whether amantadine hydrochloride (100 mg bid) demonstrated sufficient clinical efficacy compared to placebo recommend development as a pharmacotherapy for cocaine dependence. Participants were randomized (n=34) or (n=35) conditions in 16-week, placebo-controlled, double blind with three times per week group counseling. Amantadine-treated participants retained significantly longer than placebo. Based on results of joint probability index urine drug testing (i.e. the proportion cocaine-metabolite free samples divided by number assigned condition), found be more likely abstinent last day 8-weeks treatment Results at end 16 weeks similar. Standard measures consistently favored condition over placebo, although not levels statistical significance. There was no significance infrequency severity reported adverse events condition. exhibited greater reductions global staff ratings dependence from baseline termination significant differences frequency These provide moderate support further study